


1
2
3 1. A method for the treatment and/or prophylaxis of
4 cardiovascular diseases ^{and/or atherosclerosis} or eating disorders in a human or
5 non-human mammal, which comprises administering to said
6 human or non-human mammal in need thereof, an effective,
7 non-toxic amount of a compound of formula (I):



8
9
10
11
12
13
14
15 or a tautomeric form thereof and/or a pharmaceutically
16 acceptable salt thereof and/or a pharmaceutically
17 acceptable solvate thereof, wherein:

18
19 A¹ represents a substituted or unsubstituted aromatic
20 heterocyclyl group;

21
22 R¹ represents a hydrogen atom, an alkyl group, an acyl
23 group, an aralkyl group, wherein the aryl moiety may be
24 substituted or unsubstituted, or a substituted or
25 unsubstituted aryl group;

26 R² and R³ each represent hydrogen, or R² and R³ together
27 represent a bond;


28 A² represents a benzene ring having in total up to five
29 substituents; and

30 n represents an integer in the range of from 2 to 6.


31
32 2. A method according to claim 1, wherein A¹ in the
33 compound of formula (I) represents a substituted or
34 unsubstituted, single or fused ring aromatic heterocyclyl
35 group comprising up to 4 hetero atoms in the ring
36 selected from oxygen, sulphur or nitrogen.

37


3. A method according to claim 1, wherein A¹ in the compound of formula (I) represents a moiety of formula (a), (b) or (c):



(a)



(b)



(c)

wherein:


R⁴ and R⁵ each independently represents a hydrogen atom, an alkyl group or a substituted or unsubstituted aryl group or when R⁴ and R⁵ are each attached to a carbon atom, then R⁴ and R⁵ together with the carbon atoms to which they are attached form a benzene ring wherein each carbon atom represented by R⁴ and R⁵ together may be substituted or unsubstituted; and in the moiety of formula (a) X represents oxygen or sulphur.

4.

A method according to claim 3, wherein R⁴ and R⁵ in (a), (b) or (c) each independently represent hydrogen, alkyl or a substituted or unsubstituted phenyl group.

5.

A method according to claim 3, wherein R⁴ and R⁵ in (a), (b) or (c) together represent a moiety of formula (d):



(d)

1 wherein R^6 and R^7 each independently represent hydrogen,
2 halogen, substituted or unsubstituted alkyl or alkoxy.

3

4 6. A method according to claim 5, wherein R^6 and R^7 in
5 (d) each represent hydrogen.

6

7 7. A method according to claim 1, wherein A^2 in the
8 compound of formula (I) represents a moiety of formula (e):


9

10

11

12

13



(e)

14 wherein R^8 and R^9 each independently represent hydrogen,
15 halogen, substituted or unsubstituted alkyl or alkoxy.

16

17 8. A method according to claim 7, wherein R^8 and R^9 in
18 (e) each represent hydrogen.

19

20 9. A method according to claim 1, of formula (II):

21

22

23


24

25

26

27

28



(II)

29 or a tautomeric form thereof and/or a pharmaceutically
30 acceptable salt thereof and/or a pharmaceutically acceptable
31 solvate thereof, wherein A^1 , R^1 , R^2 , R^3 and n are as defined
32 in relation to formula (I) in claim 1 and R^8 and R^9 are as
33 defined in relation to formula (e) in claim 7.

34

1 10. A method according to claim 1, wherein n in the
2 compound of formula (I) represents an integer 2 or 3.

3

4 11. A method according to claim 1, wherein R¹ in the
5 compound of formula (I) represents a methyl group.

6

7 12. A method according to claim 1 which comprises the
8 administration of a compound selected from the group
9 consisting of:

10

11 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]
12 benzyl)-2,4-thiazolidinedione;

13

14 5-(4-[2-(N-methyl-N-(2-benzothiazolyl)amino)ethoxy]
15 benzylidene)-2,4-thiazolidinedione;

16

17 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]
18 benzyl)-2,4-thiazolidinedione;

19

20 5-(4-[2-(N-methyl-N-(2-benzoxazolyl)amino)ethoxy]
21 benzylidene)-2,4-thiazolidinedione;

22

23 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]
24 benzyl)-2,4-thiazolidinedione;

25

26 5-(4-[2-(N-methyl-N-(2-pyrimidinyl)amino)ethoxy]
27 benzylidene)-2,4-thiazolidinedione;

28

29 5-(4-(2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
30 ethoxy]benzyl)-2,4-thiazolidinedione;

31

32 5-(4-[2-(N-methyl-N-[2-(4,5-dimethylthiazolyl)]amino)
33 ethoxy]benzylidene)-2,4-thiazolidinedione;

34

- 1 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]benzyl)
- 2 -2,4-thiazolidinedione;
- 3
- 4 5-(4-[2-(N-methyl-N-(2-thiazolyl)amino)ethoxy]
- 5 benzylidene)-2,4-thiazolidinedione;
- 6
- 7 5-[4-(2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)
- 8 ethoxy]benzyl]-2,4-thiazolidinedione;
- 9
- 10 5-(4-[2-(N-methyl-N-(2-(4-phenylthiazolyl))amino)
- 11 ethoxy]benzylidene)-2,4-thiazolidinedione;
- 12
- 13 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]
- 14 amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 15
- 16 5-(4-[2-(N-methyl-N-[2-(4-phenyl-5-methylthiazolyl)]
- 17 amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 18
- 19 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]
- 20 amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 21
- 22 5-(4-[2-(N-methyl-N-[2-(4-methyl-5-phenylthiazolyl)]
- 23 amino)ethoxy]benzylidene)-2,4-thiazolidinedione;
- 24
- 25 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]
- 26 amino)ethoxy]benzyl)-2,4-thiazolidinedione;
- 27
- 28 5-(4-[2-(N-methyl-N-[2-(4-methylthiazolyl)]amino)
- 29 ethoxy]benzylidene)-2,4-thiazolidinedione;
- 30
- 31 5-[4-(2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)
- 32 ethoxy]benzyl]-2,4-thiazolidinedione;
- 33

- 1 5-(4-[2-(N-methyl-N-[2-(5-phenyloxazolyl)]amino)
- 2 ethoxy]benzylidene)-2,4-thiazolidinedione;
- 3
- 4 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)
- 5 ethoxy]benzyl)-2,4-thiazolidinedione;
- 6
- 7 5-(4-[2-(N-methyl-N-[2-(4,5-dimethyloxazolyl)]amino)-
- 8 ethoxy]benzylidene)-2,4-thiazolidinedione;
- 9
- 10 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzyl]-2,4-
- 11 thiazolidinedione;
- 12
- 13 5-[4-(2-(2-pyrimidinylamino)ethoxy)benzylidene]-2,4-
- 14 thiazolidinedione;
- 15
- 16 5-(4-[2-(N-acetyl-N-(2-pyrimidinyl)amino)ethoxy]benzyl)
- 17 -2,4-thiazolidinedione;
- 18
- 19 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)
- 20 benzylidene)-2,4-thiazolidinedione;
- 21
- 22 5-(4-(2-(N-(2-benzothiazolyl)-N-benzylamino)ethoxy)
- 23 benzyl)-2,4-thiazolidinedione;
- 24
- 25 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]
- 26 benzyl)-2,4-thiazolidinedione;
- 27
- 28 5-(4-[3-(N-methyl-N-(2-benzoxazolyl)amino)propoxy]benzyliden
- 29 e)-2,4-thiazolidinedione;
- 30
- 31 5-(4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl)-
- 32 -2,4-thiazolidinedione;
- 33

2
178
30

- 1 5-(4-[2-(N-methyl-N-(2-pyridyl) amino) ethoxy]benzyl-
- 2 idene)-2,4-thiazolidinedione;
- 3
- 4 5-(4-[4-(N-methyl-N-(2-benzoxazolyl) amino) butoxy]
- 5 benzylidene)-2,4-thiazolidinedione;
- 6
- 7 5-(4-[4-(N-methyl-N-(2-benzoxazolyl) amino) butoxy]-
- 8 benzyl)-2,4-thiazolidinedione;
- 9
- 10 5-(4-[2-(N-(2-benzoxazolyl) amino) ethoxy]benzylidene)-
- 11 2,4-thiazolidinedione;
- 12
- 13 5-(4-[2-(N-(2-benzoxazolyl) amino) ethoxy]benzyl)-2,
- 14 4-thiazolidinedione; and
- 15
- 16 5-(4-[2-(N-isopropyl-N-(2-benzoxazolyl) amino) ethoxy]
- 17 benzyl)-2,4-thiazolidinedione; or a tautomeric form
- 18 thereof and/or a pharmaceutically acceptable salt thereof
- 19 and/or a pharmaceutically acceptable solvate thereof.
- 20

[Handwritten signature and initials]